87 related articles for article (PubMed ID: 29698702)
1. A dimeric form of a small-sized protein binder exhibits enhanced anti-tumor activity through prolonged blood circulation.
Kim TY; Seo HD; Lee JJ; Kang JA; Kim WS; Kim HM; Song HY; Park JM; Lee DE; Kim HS
J Control Release; 2018 Jun; 279():282-291. PubMed ID: 29698702
[TBL] [Abstract][Full Text] [Related]
2. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.
Lee JJ; Kim HJ; Yang CS; Kyeong HH; Choi JM; Hwang DE; Yuk JM; Park K; Kim YJ; Lee SG; Kim D; Jo EK; Cheong HK; Kim HS
Mol Ther; 2014 Jul; 22(7):1254-1265. PubMed ID: 24682171
[TBL] [Abstract][Full Text] [Related]
3. Genetically engineered and self-assembled oncolytic protein nanoparticles for targeted cancer therapy.
Lee JJ; Kang JA; Ryu Y; Han SS; Nam YR; Rho JK; Choi DS; Kang SW; Lee DE; Kim HS
Biomaterials; 2017 Mar; 120():22-31. PubMed ID: 28024232
[TBL] [Abstract][Full Text] [Related]
4. Prolonged half-life of small-sized therapeutic protein using serum albumin-specific protein binder.
Kim TY; Park JH; Shim HE; Choi DS; Lee DE; Song JJ; Kim HS
J Control Release; 2019 Dec; 315():31-39. PubMed ID: 31654685
[TBL] [Abstract][Full Text] [Related]
5. Alkaline phosphatase-fused repebody as a new format of immuno-reagent for an immunoassay.
Seo HD; Lee JJ; Kim YJ; Hantschel O; Lee SG; Kim HS
Anal Chim Acta; 2017 Jan; 950():184-191. PubMed ID: 27916124
[TBL] [Abstract][Full Text] [Related]
6. Genetically functionalized ferritin nanoparticles with a high-affinity protein binder for immunoassay and imaging.
Kim JW; Heu W; Jeong S; Kim HS
Anal Chim Acta; 2017 Oct; 988():81-88. PubMed ID: 28916107
[TBL] [Abstract][Full Text] [Related]
7. Controlling macromolecular topology with genetically encoded SpyTag-SpyCatcher chemistry.
Zhang WB; Sun F; Tirrell DA; Arnold FH
J Am Chem Soc; 2013 Sep; 135(37):13988-97. PubMed ID: 23964715
[TBL] [Abstract][Full Text] [Related]
8. Anti-Human VEGF Repebody Effectively Suppresses Choroidal Neovascularization and Vascular Leakage.
Hwang DE; Ryou JH; Oh JR; Han JW; Park TK; Kim HS
PLoS One; 2016; 11(3):e0152522. PubMed ID: 27015541
[TBL] [Abstract][Full Text] [Related]
9. Site-Specific Lipidation of a Small-Sized Protein Binder Enhances the Antitumor Activity through Extended Blood Half-Life.
Kim TY; Nam YR; Park JH; Lee DE; Kim HS
ACS Omega; 2020 Aug; 5(31):19778-19784. PubMed ID: 32803073
[TBL] [Abstract][Full Text] [Related]
10. Protein binder for affinity purification of human immunoglobulin antibodies.
Heu W; Choi JM; Lee JJ; Jeong S; Kim HS
Anal Chem; 2014 Jun; 86(12):6019-25. PubMed ID: 24877609
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
[TBL] [Abstract][Full Text] [Related]
12. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy.
Lee JJ; Choi HJ; Yun M; Kang Y; Jung JE; Ryu Y; Kim TY; Cha YJ; Cho HS; Min JJ; Chung CW; Kim HS
Angew Chem Int Ed Engl; 2015 Oct; 54(41):12020-4. PubMed ID: 26315561
[TBL] [Abstract][Full Text] [Related]
14.
Pyo A; Yun M; Kim HS; Kim TY; Lee JJ; Kim JY; Lee S; Kwon SY; Bom HS; Kim HS; Kim DY; Min JJ
J Nucl Med; 2018 Feb; 59(2):340-346. PubMed ID: 28916621
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeling and preliminary biodistribution study of
Mushtaq S; Rho JK; Kang JA; Lee JJ; Kim JY; Nam YR; Yun SJ; Lee GH; Park SH; Lee DE; Kim HS
Bioorg Med Chem Lett; 2017 Nov; 27(22):5060-5064. PubMed ID: 29042166
[TBL] [Abstract][Full Text] [Related]
17. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.
Zahnd C; Kawe M; Stumpp MT; de Pasquale C; Tamaskovic R; Nagy-Davidescu G; Dreier B; Schibli R; Binz HK; Waibel R; Plückthun A
Cancer Res; 2010 Feb; 70(4):1595-605. PubMed ID: 20124480
[TBL] [Abstract][Full Text] [Related]
18. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
19. Encapsulated paclitaxel nanoparticles exhibit enhanced anti-tumor efficacy in A549 non-small lung cancer cells.
Huang G; Zang B; Wang X; Liu G; Zhao J
Acta Biochim Biophys Sin (Shanghai); 2015 Dec; 47(12):981-7. PubMed ID: 26525950
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
Han JM; Myung H; Kim S
Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
